For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Nootropic / Cognitive

FOXO4-DRI

Also known as: FOXO4-D-Retro-Inverso

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells. It is studied as a senolytic agent that selectively induces apoptosis in senescent cells while sparing normal cells.

Where to buy · live market data

Who's worth your money for FOXO4-DRI

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 6 scored sellers

$13.50/mg

$135 · 10mg · 99.9% purity

1 COA
Buy code MERIT · 10% off

Best value

Lowest $/mg among scored sellers

$11.90/mg

$119 · 10mg · 100.0% purity

Most tested

3 independent COAs on file

$27.50/mg

$275 · 10mg · 99.8% purity

3 COAs
Buy code MERIT · 15% off

Average price

$19.65/mg

Sellers

36

45-day trend

-0.4%

32 of 36 sellers have a current price· 14 stale hidden· 12 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch FOXO4-DRI

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About FOXO4-DRI

CAS

2460055-10-9

Molecular formula

C228H388N86O64

Sequence

LTLRKEPASEIAQSILEAYSQNGWANRRSGGKRPPPRRRQRRKKRG

Typical dose range

1 mg subcutaneous, repeated on alternating days (e.g. days 1, 3, 5) per cycle; original mouse research used 5 mg/kg × 3 doses

Half-life

~2–6 hours (estimated preclinical; no human PK data available)

Independent evidence

COAs for FOXO4-DRI

20 third-party tests across 9 vendors. Each card links to the full report.

All 20 COAs for FOXO4-DRI →
Measured purity 99.4%–100.0% across 12 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.68 %
Jun 2026
Janoshik Analytical Limited

For

FOXO4-DRI

by Verified Peptides· batch FOX062602108

Aggregated · 3rd-party listing
99.97 %
Apr 2026
Kovera Labs

For

FOX04-DRI

by Ion Peptide· batch FOX10-04022026

Aggregated · 3rd-party listing
99.76 %
Apr 2026
MDx BioAnalytical Laboratory Strong · HPLC

For

FOXO4-DRI

by BioLongevity Labs· batch 261153

Aggregated · 3rd-party listing
99.80 %
Mar 2026
Vanguard Laboratory Strong

For

FOXO4-DRI

by Peptidology· batch 1671

Aggregated · 3rd-party listing
99.72 %
Mar 2026
Freedom Diagnostics Moderate

For

FOX04-DRI

by Real Peptides

Aggregated · 3rd-party listing
99.81 %
Mar 2026
Janoshik Analytical Limited · HPLC

For

FOXO4-DRI

by Skye Peptides· batch FOX26-15-001

Aggregated · 3rd-party listing
99.97 %
Jan 2026
MZ Biolabs Moderate · HPLC

For

FOXO4-DRI

by Ascension Peptides· batch 55-01260229

Aggregated · 3rd-party listing
99.97 %
Jan 2026
MZ Biolabs Moderate · HPLC

For

FOXO4-DRI

by Ascension Peptides· batch 55-01260229

Aggregated · 3rd-party listing
99.89 %
Dec 2025
Freedom Diagnostics Moderate · HPLC

For

FOXO4-DRI

by Glacier Aminos· batch FOX10GA01

Aggregated · 3rd-party listing
99.50 %
Oct 2025
Freedom Diagnostics Moderate

For

FOXO4-DRI

by Kimera Chems· batch KC-FX4-GRY1

Aggregated · 3rd-party listing
99.49 %
Mar 2025
Janoshik Analytical Limited · HPLC

For

FOXO4-DRI

by Verified Peptides· batch 03-25-0110A

Aggregated · 3rd-party listing
99.44 %
Jan 2025
Freedom Diagnostics Moderate · HPLC

For

FOX-04

by Simple Peptide· batch cmp9xk4yj00329trx7cgpf22y

Aggregated · 3rd-party listing
99.88 %
Freedom Diagnostics Moderate · HPLC

For

FOXO4-DRI

by Peptide Tech· batch F4D-5195

Aggregated · 3rd-party listing
99.80 %
MDx BioAnalytical Laboratory Strong · HPLC

For

FOXO4-DRI

by BioLongevity Labs· batch cmojb7f8i01b6kirxq6ddannn

Aggregated · 3rd-party listing
99.80 %
Vanguard Laboratory Strong

For

FOXO4-DRI

by Kimera Chems· batch Black Cap

Aggregated · 3rd-party listing
99.49 %
SafeCert Labs Moderate · HPLC

For

FOXO4-DRI

by BioLongevity Labs· batch cmojb7qk401dukirxq2vhxw8n

Aggregated · 3rd-party listing
Mar 2026

Purity not on file

Freedom Diagnostics Moderate

For

FOX04-DRI

by Real Peptides

Aggregated · 3rd-party listing
Mar 2026

Purity not on file

Janoshik Analytical Limited

For

FOXO4-DRI

by Skye Peptides· batch FOX26-15-001

Aggregated · 3rd-party listing
Jan 2026

Purity not on file

Freedom Diagnostics Moderate

For

FOXO4-DRI

by Peptide Tech· batch F4D-5195

Aggregated · 3rd-party listing
Mar 2025

Purity not on file

Janoshik Analytical Limited

For

FOXO4-DRI

by Verified Peptides· batch 03-25-0110A

Research depth

12 citations indexed for FOXO4-DRI

All research on FOXO4-DRI →

review · 2026

Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline

Cellular senescence, driven by the interaction between FOXO4 and p53, is increasingly recognized as a crucial mechanism in brain aging and the development of neurodegenerative disorders.

Study · 2026

Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence

Temozolomide (TMZ) is still the first-line drug for glioblastoma (GBM) treatment though tumor cell resistance remains a major challenge.

review · 2026

The right time, the right cell: the potential for precision senotherapy in pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a fatal vasculopathy driven by proinflammatory signaling that leads to pulmonary vascular remodeling and ultimately, right ventricular failure. Existing therapies fail to eliminate dysfunctional cells or reverse pathologic remodeling.

animal · 2025

FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway

Objectives Endothelial cell dysfunction during aging is a key driver of vascular aging and related diseases; however, effective strategies to selectively eliminate senescent endothelial cells and restore vascular function remain lacking.

Study · 2025

The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI

A central process contributing to the phenotype of aging is cellular senescence. We recently identified the FOXO4 - p53 axis as pivotal in maintaining the viability of senescent cells, and that senescent cells can be targeted selectively with the senolytic peptide FOXO4-DRI.

Study · 2025

FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation

Keloids are pathological scars exhibiting tumour-like aggressiveness and high recurrence rate.